Abstract The goal of this study was to compare the efficacy and toxicity of chemotherapy to exemestane plus everolimus (EXE/EVE) through a network meta-analysis (NMA) of randomized controlled trials. NMA methods extend standard pairwise meta-analysis to allow simultaneous comparison of multiple treatments while maintaining randomization of individual studies. The method enables ''direct'' evidence (i.e., evidence from studies directly comparing two interventions) and ''indirect'' evidence (i.e., evidence from studies that do not compare the two interventions directly) to be pooled under the assumption of evidence consistency. We used NMA to evaluate progression-free survival (PFS) and time to progression (TTP) curves in 34 studies, and response rate (RR) and the hazard ratios (HRs) of the PFS/TTP in 36 studies. A number needed to treat (NNT) analysis was also performed as well as descriptive comparison of reported toxicities. The NMA for PFS/TTP curves and for HR shows EXE/EVE is more efficacious than capecitabine plus sunitinib, CMF, megestrol acetate and tamoxifen, with an average of related-PFS/TTP difference ranging from about 10 months for capecitabine plus sunitinib to more than 6 months for tamoxifen. The NMA for overall RR shows that EXE/EVE provides a better RR than bevacizumab plus capecitabine, capecitabine, capecitabine plus sorafenib, capecitabine plus sunitinib, CMF, gemcitabine plus epirubicin plus paclitaxel, EVE plus tamoxifen, EXE, FEC, megestrol acetate, mitoxantrone, and tamoxifen. Finally, the NMA for NNT shows that EXE/EVE is more beneficial as compared to BMF, capecitabine, capecitabine plus sunitinib, CMF, FEC, megestrol acetate, mitoxantrone, and tamoxifen. The combination of EXE/EVE as first-or second-line therapy for ER?ve/HER2-ve metastatic breast cancer is more efficacious than several chemotherapy regimens that were reported in the literature. Toxicities also favored EXE/EVE in most instances.
Introduction
Many improvements have been made in the treatment of hormone receptor (HR)?ve metastatic breast cancer (MBC) in the past 15 years. Novel aromatase inhibitors (AIs) and drugs that target specific pathways (i.e., mTOR and CDK4/6 inhibitors) become available, and new chemotherapies were introduced (ixabepilone and eribulin) along with highly effective HER2-targeted combination therapies for HER2?ve cancers including the HR?ve/ HER2?ve tumors. These novel therapies improved response rates (RRs) and increased median progressionfree survival (PFS) with variable but often modest or added toxicity [1, 2] . The preponderance of first-line treatment options also poses challenges on how to sequence the several effective therapies. Based on data from the BOLERO-2 trial, the mTOR inhibitor everolimus (EVE) in combination with exemestane (EXE) was approved by the US Food and Drug Administration and European Medicines Agency to treat postmenopausal women with HR?ve/ HER2-ve advanced breast cancer that recurred or progressed during or after a non-steroidal AI therapy [3] . The combination of EXE/EVE has doubled the median PFS compared to EXE/placebo at 18 months median follow-up, with good health-related quality of life (HRQoL), and a consistent efficacy in all predefined patient subgroups (i.e., visceral metastases, patients with bone disease, and elderly patients) [4] [5] [6] . Moreover, the improvement on PFS by the EXE/EVE has been also confirmed into the final analysis performed by Yardley et al. [4] . However, several chemotherapy regimens exist that also produce substantial clinical benefit as first-line therapy for HR?ve MBC. In some instances, for example, in patients with extensive visceral metastasis, chemotherapy can even be considered as the preferred option [7] [8] [9] [10] [11] . Up to now, chemotherapy has not been compared with endocrine therapy in combination with targeted therapy (e.g., EXE/EVE) as first-line treatment for MBC in randomized trials; only two trials are ongoing comparing endocrine therapy plus a target agent (EVE or palbociclib) versus capecitabine (see: www.clin icaltrial.gov), but the data are not ready yet. However, a trial including exclusively patients in first line for MBC is unlikely to be performed. Furthermore, there is no single optimal first-line chemotherapy for MBC in general and choice of drugs depends on patient characteristics, prior treatment variables, and patients preference. The purpose of this study was to perform a network meta-analysis (NMA) of the existing literature to indirectly compare the efficacy and safety of EXE/EVE with chemotherapy agents as first or second-line therapy for HR?ve MBC.
Methods
Health care decision makers are often faced with the challenge of assessing competing interventions in the absence of an randomized controlled trial (RCT) comparing all interventions of interest simultaneously in a head-tohead fashion. When the available RCTs of interest do not all compare the same interventions but each trial compares only a subset of the interventions of interest, it is possible to develop a network of RCTs where all trials have at least one intervention in common with another. Such a network allows for indirect comparisons of interventions not studied in a head-to-head fashion [18] . Therefore, NMA is a generalization of standard pairwise meta-analysis that allows pooling both the direct and indirect evidence available for a given intervention. Even when direct evidence is available for some interventions of interest, combining these with indirect comparisons in a NMA may yield a more refined and precise estimate for the corresponding relative treatment effects. For these reasons, NMA has become one of the most important tools used in cost-effectiveness decision making to effectively exploit all the evidence available for a given treatment [12] [13] [14] [15] .
A Bayesian NMA framework was used for each endpoint considered: the tumor RR, the hazard ratio (HR) of PFS/time to progression (TTP), and the whole PFS/TTP curve. Additionally, using the results of the latter analysis, a meta-analysis of the number needed to treat (NNT) was also performed for EVE plus EXE versus each one of the other therapies described in the previous sections. The NNT is the average number of patients needed to be treated to prevent an adverse outcome in one additional patient compared to a control treatment group.
An extensive description of the methods used and the associated references are available in the Supplemental Material Section.
Results
Among 8910 papers/abstracts evaluated, 44 published papers were included into the NMA. Non-randomized studies or studies with insufficient or inconsistent data on PFS/TTP have been excluded from the analysis. Finally, 34 and 36 studies were considered for the analysis of the entire PFS/TTP curve and for the analysis of RR and HR of PFS/ TTP, respectively. Unfortunately, in the reported chemotherapy-based studies the proportion of ER?ve BC were not specified; moreover in some older studies, the BC classification with regards to the HER2 signaling is not described, thus including also HER2?ve patients. The characteristics of each study design are listed in Tables 1  and 2 . All patients included have ER?ve/HER2-ve MBC in their first or second line of treatment. To create the network for the comparison of the EXE/EVE combination with the chemotherapy-based regimes, we decided to include the paper published by Dixon et al. [16] (even though published in 1992), as it is the only study available which compared endocrine therapy versus chemotherapy in MBC with regards to PFS/TTP and RR/HRs of PFS/TTP, respectively (Fig. 1a, b) . Network meta-analysis (NMA) of the whole PFS/ TTP curves
The reported Kaplan-Meier curves were digitized to perform a NMA involving the whole PFS/TTP curves (Figs. S1A, S1B). The DIC values for the fixed and random effects are reported in Table S1 . The values showed that the fractional polynomial model with fixed effects provided the best fit to the data. The estimated HRs (not reported) showed that for many treatments the assumption of proportional hazards is not tenable due to the markedly change of HRs through time, suggesting that the use of this more flexible methodology is more appropriate than the analysis based on the HRs alone. Table S2A ), the estimates of the difference in the expected PFS/TTP between EXE/EVE versus each single chemotherapy-based treatment are represented. The estimated PFS/TTP curves were extrapolated up to 60 months.
According to these results, the combination of EVE with EXE is projected to be more efficacious than either capecitabine plus sunitinib, or CMF, or megestrol acetate or tamoxifen, with an average expected PFS/TTP difference ranging from about 10 months for capecitabine plus sunitinib to slightly more than 6 months for tamoxifen. In BOLERO-2 trial, the comparison was direct between EVE/ EXE and EXE alone, leading to a difference of PFS of about 4 months. As regards the combination CAP/SUN, for example, the NMA incorporates this result in the comparison versus EVE/EXE through all the comparisons in the pathway that links these two treatments (see pathway in Fig. 1a : EVE/EXE vs. EXE, EXE vs. MA, MA vs. mitoxantrone, mitoxantrone vs. FEC, CAP vs. CAP/SUN) leading to the difference of about 10 months of PFS/TTP in favor of EVE/EXE (in this case, the NMA estimated difference of PFS/TTP in favor of EVE/EXE vs. CAP/SUN is higher than the one reported by BOLERO-2 for EVE/EXE vs. EXE alone but the comparators for EVE/EXE are not the same).
When compared to other chemotherapies, there is a trend in favor of EVE plus EXE, although the 95 % credible intervals, CrIs [17] include zero, suggesting that EVE with EXE is expected to be at least as efficacious as these alternatives.
Network meta-analysis (NMA) of overall response rates
For the NMA of the RRs, we used a binomial likelihood for the number of patients who responded. We used the fixed effects model as it provided a slightly better fit to the data than the random effects model (DIC for fixed effects model = 514.021, DIC for random effects model = 515.242). Estimates of the posterior means and medians, together with the CrIs of the odds ratios of each treatment versus the combination EVE plus EXE are reported in Fig. 2b and in Table  S2B .
Overall these results suggest that the combination of EVE plus EXE provides a better RR than bevacizumab plus capecitabine, capecitabine, capecitabine plus sorafenib, capecitabine plus sunitinib, CMF, gemcitabine plus epirubicin plus paclitaxel, EVE plus tamoxifen, EXE, FEC, megestrol acetate, mitoxantrone, or tamoxifen. There is no clear evidence for the other chemotherapy-based treatments to be more efficacious than the combination of EVE plus EXE.
Network meta-analysis (NMA) of hazard ratios for PFS/TTP
For the NMA of the HRs, we assumed that the log HRs are normally distributed with the log HR mean equaling the true log HR observed in each study and the variance equaling the observed variability in each study. The fixed effects model provided a slightly better fit to the data, as confirmed by the DIC values (2.579 for the fixed and 2.899 for the random effects model). Figure 2c (and Table S2C ) reports the estimates for the posterior means and medians, together with the 80 and 95 % CrIs for the HRs of each treatment versus the combination EXE/EVE. The results suggest that EVE plus EXE has lower HRs than capecitabine, capecitabine plus sunitinib, CMF, EVE plus tamoxifen, EXE, megestrol acetate, Network meta-analysis (NMA) of number needed to treat (NNT)
Based on the estimated PFS/TTP curves from the previous analysis, we also computed the NNT for EXE/EVE versus the other chemotherapy-based treatments. We evaluated the NNT for every month up to 17 months, which was the maximum follow-up time available in the BOLERO-2 trial [3] . Figure 3 provides the estimated posterior medians of the NNT for all months, and it is possible to postulate that the combination of EXE/EVE produces a permanent positive NNT, ranging from 1 to about 8, even if for most of the competing treatments it is below 4. Table 3 reports the posterior medians and the 95 % CrIs for the NNT of EVE plus EXE versus each single chemotherapy treatment at 3, 9, and 15 months, respectively. The results suggest that EVE plus EXE is more beneficial (i.e., it has a positive NNT) for all the three periods considered with regards to BMF, capecitabine, capecitabine plus sunitinib, CMF, FEC, megestrol acetate, mitoxantrone, and tamoxifen. Additionally, there is also evidence that EVE plus EXE provides an increased benefit when compared to many of the remaining treatments in at least one of the three periods considered. Moreover, there is no clear evidence that the combination of EXE/EVE is more detrimental than any of the other treatments.
Risk of bias assessment
The risk of bias assessment for the eligible studies is presented in Figs. S2 and S3. Eighteen studies were open-label studies without blinding of patients and personnel. In six Fig. 2 cases, PFS and tumor RR were assessed locally without an independent review and one study reported that robust assessment of PFS was not feasible due to the lack of regular imaging. Twenty-six studies showed a bias in the selection of the results since they did not report overall survival (OS) or PFS curves or related HRs. Regarding the assessment of adverse events, almost all of the studies did not report clearly if measures were taken to ensure the ''blindness'' of the evaluators.
Exploratory evaluation of adverse events
The studies included in the NMA reported the adverse events [18] heterogeneously, thus we have focused on the reported AEs of grade 3/4 only, for the combination of EXE/EVE and for the other chemotherapy-based trials. A systematic assessment of the safety of EXE/EVE versus all the other treatments through a NMA was not feasible since few studies did not report information on AEs at all or explicitly on AEs of grade 3/4 or for the considered therapeutic schemes, leading to a limited connected network of studies. The analysis of AEs has been restricted to an exploratory evaluation of the percentages of patients affected. The data are shown in Table 4 separately for biochemical changes and hematologic and non hematologic events. In case different studies reported different percentages for the same treatment, ranges (min-max) were reported. The combination of EXE/EVE showed less AEs if compared to chemotherapy-based treatment, especially versus regimens containing nab-paclitaxel or bevacizumab.
Discussions
Even with modern therapies, very few patients are cured of MBC; treatment is palliative with the goals of symptom relief and possibly prolongation of life. The challenge for the clinicians is to balance treatment-related toxicity with the likelihood of benefit and cancer-related symptom relief from therapy. For these reasons, endocrine therapy should be adopted as the preferred initial treatment for ER?ve MBC as mentioned in international guidelines [19] . However, Andre et al., although endocrine therapy is predominantly used (69 %), showed that the clinical choice of treatment in first line is still a matter of discussion between chemotherapy versus endocrine therapy in Europe [20] . AIs have become the most frequently used first-line endocrine therapy of MBC in postmenopausal women because they increase PFS compared with tamoxifen [21, 22] . Recently, the combination of EXE/EVE showed a significant improvement of PFS in MBC compared to EVE alone. Bachelot et al. also showed in a NMA that the combination of EXE/EVE has higher PFS/TTP compared to fulvestrant alone [10] .
Partridge et al. stated the expert consensus opinion that endocrine therapy is preferable to chemotherapy in the early lines of MBC treatment [11] ; however, few randomized clinical trials compared directly these two different treatment modalities. Based on the report recently published by Cope et al. [23] about the feasibility of performing NMA of RCTs to synthesize direct and indirect
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Number needed to treat (NNT) Assuming that PFS is a clinically important measure of drug efficacy [24] ; in our analysis, the EXE/EVE combination was at least as efficacious as any chemotherapy given alone or in combination. This observation is reproduced in the NMA of HR for PFS/TTP and in the NMA for RR. The analysis did not show any clear evidence for the other chemotherapies to be better than the combination of EXE/EVE. It is projected that EXE/EVE is superior to CMF (95 % CrIs 0.96-17.25) or to capecitabine (95 % CrIs 1.24-13.89) in terms of median PFS/ TTP or HR of PFS/TTP, respectively. It showed also superiority to single-agent capecitabine (95 % CrIs 1.41-16.55) (95 % CrIs 0.01-0.43) in term of HR of PFS/TTP or RR, respectively. EXE/EVE also appeared to be more efficacious than FEC (95 % CrIs 0.01-0.51) for RR and equal for HR and for PFS/TTP. In the NMA analysis, EXE/EVE is projected to be as efficacious as any of the chemotherapy regimens containing a taxane [17, 25] . The combination was slightly inferior to nab-paclitaxel as second-line treatment of MBC [26, 27] (95 % CrIs 0. 16-3.46) . However, it is known the taxanecombined regimens are superior to taxane in monotherapy for TTP [28] , PFS, and RR rates [29, 30] , and in OS [31] , even further evaluations are required with regards to estrogen receptor status [32] .
In the NMA analysis, all the RCTs were considered, even those with the combination of target therapies, such as bevacizumab, sunitinib, sorafenib, etc. So far, no targeted therapy has shown to enhance chemotherapy outcome in HER2-ve breast cancer except for bevacizumab [33, 34] . The addition of bevacizumab to chemotherapy, such as taxane or capecitabine, has demonstrated improvements in RR and PFS in both first-and second-line therapy [33] [34] [35] , which are considered surrogate parameters for OS [36] . However, bevacizumab has no significant impact on OS or HRQoL, which are indicators of a direct patient benefit. For this reason, the clinical value of bevacizumab for MBC remains controversial. The results observed with the combination of EXE/EVE appears to be superior or at least as efficacious as the results with the combination of bevacizumab and capecitabine or taxane as described in the NMA for RR, HR of PFS/TTP, and PFS/TTP curves. Moreover, the combination showed to have a significant positive impact on HRQoL of the patients although associated with moderate but manageable side effects [37] . As shown in the expanded access BALLET trial, the onset of the adverse events was mainly confined into the first 3 months of treatment with regards to the EXE/EVE regimen with a reduction in terms of number of events during the following months [38] . On the counterpart, the AEs related to chemotherapy last for all the duration of treatment with an increased grade of toxicity in case of a maintenance scheme [39] .
In the meta-analysis by Gennari et al., it has been shown that longer planned treatment durations have been associated with significant increases in OS and PFS [40] . The NMA of NNT showed clearly that the combination of EVE plus EXE provides an increased benefit when compared to chemotherapy over time.
As the choice of the treatment in MBC is determined by multiple factors such as the prior therapy, the toxicity, the performance status, the comorbid conditions, the patient preference, and the impact on patients' benefit such as OS or HRQoL, the combination of EXE/EVE could be taken into account, not only for its manageability, but also when the clinician would have to plan a longer duration of the therapy.
However, performing this NMA, we have found three limitations: (1) the combination of two different outcome measures such as the PFS and the TTP. Although PFS and TTP can have dissimilar results because deaths are not typically included in TTP, the two outcome measures had overlapping criteria for disease-specific deaths; therefore, the majority of on study deaths were assumed to be disease-specific, and the analysis assumed that PFS and TTP would be the same, (2) the data related to the HRs are based on the proportional hazards assumption of a constant ratio of the hazard rates for the two compared treatments. Many times this assumption is implausible, because the data provide evidence of an opposite situation, i.e., a ratio of the hazard rates that changes with time, thus we had to add a NMA involving the whole PFS/TTP curves rather than their HR summary measure, (3) in the earliest chemotherapy-based trials, the modern classification of BC was not used; therefore up to 20 % of the enrolled patients may be HER2?ve. However, the combination of EXE/ EVE is confined to ER?ve/HER2-ve MBC, whereas the chemotherapy-based regimens were administered in MBC without any specific report to the ER and HER2 status. Only few authors reported the RR or the PFS-related HRs data with regards to ER or HER2 expression, thus we assumed that the two population could be comparable even they are strictly not. Thus, this indirect comparison is subject to caution.
In conclusion, this indirect treatment comparison suggests that EVE in combination with EXE may be more efficacious (or at least as beneficial as) than some of the chemotherapy agents alone or in combination as polychemotherapy or in association with targeted therapies in postmenopausal women with HR?ve/HER2-ve advanced breast cancer for their first/second line of treatment. Moreover, the combination seems to have less AEs or more manageable grade 3/4 treatment-related toxicities in agreement with the recent analyses where hormone-therapy was associated with better patient-reported outcomes than chemotherapy in first-line MBC management, and these findings should be taken into consideration while making treatment decisions for ER?ve/HER2-ve MBC [41] .
Future trials should be based on the randomization comparing the best endocrine-based therapy available versus chemotherapy-based treatment maybe combined with most promising targeted agents as first-line treatment for only ER?ve/HER2-ve MBC (as in the PEARL study and BOLERO-6 study). A selective combination of these therapies should be evaluated in order to define an optimal treatment strategy in terms of outcome and also HRQoL. However, given the heterogeneity of breast cancer, even when restricted to specific subtypes, it is also possible that the same best therapeutical approach for most patients does not exist. Instead, in the genomic era, the molecular diagnosis of the tumor may potentially allow in the future to select a specific drug which will best fit with the specific disease of any single patient.
Key issues
• Several chemotherapy regimens are used as first-line therapy for postmenopausal women with ER?ve MBC. Up to now, results of randomized trials comparing chemotherapy with endocrine therapy in combination with targeted therapy are not yet available but expected in the near future (ex. BOLERO-6).
• The NMA indirectly compares the efficacy and safety of EXE/EVE with chemotherapy agents as first-or second-line therapy for ER?ve/HER2-ve MBC.
• Concerning the analysis of PFS/TTP curves or ORR or HRs, the combination of EXE and EVE is more efficacious than (or at least as beneficial as) some of the chemotherapy agents alone or in combination or in association with targeted therapies in postmenopausal women with ER?ve/HER2-ve advanced breast cancer for their first/second line of treatment.
• The analysis on the NNT revealed that EXE/EVE at 3, 9, and 15 months is more beneficial with regards to several chemotherapy-based regimes.
• An exploratory evaluation of the safety of EXE/EVE versus all the other treatments showed that EXE/EVE reported less adverse events if compared to chemotherapy-based treatments.
